China Meheco Group (SHA:600056), through subsidiary Tianfang Pharmaceutical, received two drug supplementary approvals for clindamycin phosphate injection after passing the Chinese drug regulator's consistency evaluation for quality and efficacy, according to a Shanghai bourse filing on Tuesday.
The approvals are for the drug's two specifications 4 milliliters and 2 milliliters.
The drug is used to treat serious infections caused by susceptible anaerobic bacteria, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.